Skip to main content
Top
Published in: Indian Journal of Pediatrics 10/2022

25-04-2022 | Herpes Virus | Clinical Brief

Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children

Authors: Paula Carrascosa-García, Lidia Oviedo-Melgares, David Torres-Fernández, Daniel Blázquez-Gamero, Thaís Armangué, Sara Vila-Bedmar, Luis Prieto-Tato, Concepción Miranda-Herrero, Mar Santos-Sebastián, Elena María Rincón-López, Elisa Fernández-Cooke

Published in: Indian Journal of Pediatrics | Issue 10/2022

Login to get access

Abstract

The long-term response of two infants with anti-N-methyl-D-aspartate receptor (anti-NMDAR) post herpes simplex encephalitis treated with rituximab is reported here. Rituximab may improve the course of the disease and should be considered early as second-line treatment. Data on the long-term effect of rituximab in B cell depletion and immunoglobulins levels in infants are needed.
Literature
1.
go back to reference Steiner I, Kennedy PGE, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6:1015–28.CrossRef Steiner I, Kennedy PGE, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6:1015–28.CrossRef
2.
go back to reference Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72.CrossRef Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72.CrossRef
3.
go back to reference Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for longterm outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.CrossRef Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for longterm outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.CrossRef
4.
go back to reference Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899–904.CrossRef Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899–904.CrossRef
5.
go back to reference Armangue T, Moris G, Cantarín-Extremera V, et al. Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85:1736–43.CrossRef Armangue T, Moris G, Cantarín-Extremera V, et al. Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85:1736–43.CrossRef
6.
go back to reference Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72:902–11.CrossRef Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72:902–11.CrossRef
7.
go back to reference Bartolini L. Practice Current: How do you treat anti-NMDA receptor encephalitis? Neurol Clin Pr. 2016;6:69–72.CrossRef Bartolini L. Practice Current: How do you treat anti-NMDA receptor encephalitis? Neurol Clin Pr. 2016;6:69–72.CrossRef
8.
go back to reference Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–50.CrossRef Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–50.CrossRef
9.
go back to reference Deyà-Martínez A, Gordón Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020;7:e724. Deyà-Martínez A, Gordón Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020;7:e724.
Metadata
Title
Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children
Authors
Paula Carrascosa-García
Lidia Oviedo-Melgares
David Torres-Fernández
Daniel Blázquez-Gamero
Thaís Armangué
Sara Vila-Bedmar
Luis Prieto-Tato
Concepción Miranda-Herrero
Mar Santos-Sebastián
Elena María Rincón-López
Elisa Fernández-Cooke
Publication date
25-04-2022

Other articles of this Issue 10/2022

Indian Journal of Pediatrics 10/2022 Go to the issue